Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (510)	2/15/1998 1:13:00 AM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Here is a Website for quotes on PFE options. cboe.pcquote.com BigKNY3

To: BigKNY3 who wrote (510)	2/21/1998 9:24:00 AM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Highlights from the Big Pharma Report posted on AOL's Motley Fool Pfizer Board. Have PFun! BigKNY3 _____________________________________________ Big Pharma Report- 2/21/98 Week Big Pharma continued its momentum with a 1.2% gain as compared to increases for the record Dow (+0.5%), the record S&P (+1.3%) and the almost record NAStie (+1.0%). Five of the "Healthy 13" set all-time highs; SGP (78.88), MRK (124.94), PFE (88.25), ABT (75.75), and JNJ (70.56). MRK (+5.9%) was the weekly leader amid hopes for the near-term approval of its asthma medication Singulair and notification of priority review for Aggrastat for unstable angina. PFE (+4.4%) rose on the announcement of its marketing partnership with Searle for Celebra. WLA (-2.9%) and LLY (-2.7%) were the major laggards in Big Pharma. LLY bounced off a low of 59 1/2 on news that Evista new Rx's "were running behind early weeks for Fosamax". February 1998 After the strong January (+10.7%), Big Pharma (+2.5%) continues to trail the February gains for the Dow (+6.4%) S&P (+5.5%) and the NASTie (+6.7%). GLX (+16.6%) leads the month as merger talks with SBH (+5.0%) continue. AMGN (+8.5%) is starting to bounce. PFE (+6.8%) is ranked 4th for the month ..but on the move. LLY cups the cellar (-8.8%). YTD 1998 Big Pharma (+13.5%) continues to double the Dow (+6.4%), the S&P (+6.6%) and outgains the NAStie (+10.0%). GLX (+31.1%) has regained the YTD lead from its soon to be partner SBH (+28.8%). Last year's champ SGP is showing amazing staying power (+24.7%). AMER (+24.7%) is third for no apparent rationale reason. Powerhouses MRK (+17.6%) and PFE (+17.1%) are making their moves. LLY (-11.0%) is the only Big Pharma showing a YTD decline. Big Pharma News You Can Use (BigKNY3 Comments) -Barrons lead article reports that guru Abby Cohen remains very bullish. -Gruntal reiterated a strong buy on MRK and upped its target price to 150. -The Right Line Split Report predicts that MRK will announce a 2-1 split on 2/25/98. Historically MRK splits 3-1 at higher levels. --The Wall Street Transcript issued a special issue on healthcare stocks. Some PFE highlights: -"PFE is the best out there. I see PFE as the MRK of the 90s. PFE proved that through strong focus on support of research." -"PFE is the one company that has a more balanced approach towards the industry. It's not just focused on developing newer drugs,but also on marketing them effectively. I don't think any company does it better than PFE." -Medical Marketing and Media has issued an industry outlook for 1998. General comment: "Smooth sailing ahead". Products to watch in 1998 are Evista (LLY), Viagra (PFE), Propecia (MRK), Plavik (BMY), Detrusitol (PNU), and Citalopram (Forest Labs). -The agreement between Monsanto and PFE for Celebra was no surprise to the PFEr Board. Here is a bulleted highlight from the 2/7/98 Big Pharma Report: -Business Week is highlighting the Cox-2s from MTC and MRK. PFE or LLY could become the marketing partner for MTC (Searle). -The first stock recommended on Wall Street Week last night was PFE by Martin Zweig: "I like to buy strength. I like to go with the trend. The trend is your friend." ED News You Can Use (BigKNY3 Comments) --V Day Countdown: -38 Days